BioSyent Annual General Meeting of Shareholders - June 10, 2014
June 06 2014 - 8:16AM
Marketwired
BioSyent Annual General Meeting of Shareholders - June 10, 2014
TORONTO, ONTARIO--(Marketwired - Jun 6, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) is pleased to announce that it will
be holding its Annual General and Special Meeting of Shareholders
at 9 a.m. EDT on Tuesday June 10, 2014 at the Sheraton Toronto
Airport Hotel & Conference Centre (Niagara Room) located at 801
Dixon Road, Toronto, Ontario, M9W 1J5.
Following the formal business of the meeting, CEO René Goehrum
will be making a presentation to attendees. Mr Goehrum will provide
an overview of the Company and its corporate activities.
To view and listen to a CEO presentation commenting on First
Quarter 2014 Financial Results released May 16, 2014, please visit
the following link http://www.biosyent.com/q1/.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,801,195
shares issued and outstanding.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture
Exchange assumes no responsibility for the accuracy of this release
and neither approves nor disapproves of the same.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Sep 2023 to Sep 2024